| Cat. No. |
Product Name |
Information |
| PC-38372 |
Rintodestrant
SERD
|
Rintodestrant (G1T48) is a potent, oral selective estrogen receptor degrader (SERD) with EC50 of 0.24 nM (ERα degradation, ICW), competitively binds to and degrades estrogen receptor (ER) and blocks ER signaling in ER-positive breast cancer cells. |
| PC-73421 |
Imlunestrant
SERD and ER inhibitor
|
Imlunestrant (LY3484356) is a potent, oral, selective estrogen receptor degrader (SERD) and pure estrogen receptor antagonist with Ki values of 0.64 nM and 2.8 nM against WT ERα and Y537S mutant ERα proteins, respectively. |
| PC-73108 |
SAR439859
SERD
|
SAR439859 (Amcenestrant) is a potent, orally available, selective estrogen receptor degrader (SERD) with IC50 of 0.2 nM (ERα degradation). |
| PC-73046 |
GNE-274
ER partial agonist
|
GNE-274 (GNE274) is a small molecule non-degrader, partial agonist of estrogen receptor (ER), failed to trigger increased ER turnover in tested cell line. |
| PC-72965 |
GSK5182
ERRγ inverse agonist
|
GSK5182 (GSK-5182) is a highly selective and orally active inverse agonist of estrogen-related receptor γ (ERRγ) with IC50 of 79 nM. |
| PC-72964 |
DN200434
ERRγ inverse agonist
|
DN200434 (DN-200434) is a highly potent (functional IC50=6 nM, binding IC50=40 nM), selective, biocompatible and orally available ERRγ inverse agonist. |
| PC-72914 |
TTC-352
ER mimic agonist
|
TTC-352 (TTC352) is a synthetic selective estrogen mimic acts as estrogen receptor (ER) partial agonist for the treatment of endocrine-resistant breast cancer. |
| PC-72844 |
ErSO
UPR activator
|
ErSO is a small molecule activator of the unfolded protein response (UPR), activates the a-UPR, induces rapid and selective necrosis of ERα-positive breast cancer cell lines in vitro. |
| PC-72786 |
Giredestrant
SERD
|
GDC-9545 (Giredestrant) is an efficient and potent selective estrogen receptor degrader (SERD) and a full antagonist. |
| PC-72665 |
GNE-502
ER antagonist
|
GNE-502 (GNE502) is an orally bioavailable and potent degrader for estrogen receptor positive breast cancer. |
| PC-72606 |
Camizestrant
SERD
|
AZD9833 (Camizestrant) is an orally bioavailable, highly potent, next-generation selective estrogen receptor degrader (SERD) and antagonist with both EC50 of <1 nM (ERα receptor) in MCF7 cells. |
| PC-72139 |
BC-N102
Estrogen Receptor inhibitor
|
BC-N102 is a first-in-class novel small molecule inhibitor for targeting oncogenic and hormonal signaling in ER-positive breast cancer. |
